XRCC1 and colorectal carcinoma: Genetic variants of the XRCC1 G/G polymorphism, which results in an Arg399Gln substitution has been tested for OXAIPN relevance in a study prospectively enrolling 292 Korean patients treated with FOLFOX for CRC and found that patients harboring XRCC1 23885GG experienced less grade 2–4 OXAIPN (adjusted OR:0.52, 95% CI: 0.27–0.99) [110].